Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) have received an average recommendation of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $19.50.

A number of brokerages have issued reports on ENTA. Wall Street Zen lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 22nd. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, June 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th.

Enanta Pharmaceuticals Price Performance

ENTA opened at $13.60 on Monday. The firm has a market cap of $396.03 million, a P/E ratio of -5.64 and a beta of 0.98. Enanta Pharmaceuticals has a 52 week low of $7.05 and a 52 week high of $17.15. The business has a fifty day simple moving average of $13.59 and a 200-day simple moving average of $13.48.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%.The firm had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Sell-side analysts expect that Enanta Pharmaceuticals will post -2.36 earnings per share for the current year.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its position in shares of Enanta Pharmaceuticals by 1.5% during the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after buying an additional 54,396 shares in the last quarter. Jupiter Topco LLC acquired a new position in Enanta Pharmaceuticals during the 2nd quarter worth approximately $53,252,000. BlackRock Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the 2nd quarter valued at approximately $47,304,000. Farallon Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals by 30.6% in the 4th quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock valued at $43,719,000 after purchasing an additional 650,000 shares in the last quarter. Finally, Krensavage Asset Management LLC lifted its position in shares of Enanta Pharmaceuticals by 30.8% during the 4th quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after purchasing an additional 651,946 shares during the last quarter. Hedge funds and other institutional investors own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.